Exosc9 Initiates SUMO-Dependent lncRNA TERRA Degradation to Impact Telomeric Integrity in Endocrine Therapy Insensitive Hormone Receptor-Positive Breast Cancer
Cells · 2023
DOI: 10.3390/cells12202495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Maram Quttina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nuclear Receptors & Cell Signaling, Department of Biology & Biochemistry, University of Houston, 3517 Cullen Blvd, SERC Bldg, Rm 3010, Hou…. Hauptthemen laut MEDLINE: Breast Neoplasms, RNA, Long Noncoding, Exosome Multienzyme Ribonuclease Complex, RNA-Binding Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institutes of Health, Susan G. Komen ASPIRE.
Abstract (Originalsprache)
Long, noncoding RNAs (lncRNAs) are indispensable for normal cell physiology and, consequently, are tightly regulated in human cells. Yet, unlike mRNA, substantially less is known about the mechanisms for lncRNA degradation. It is important to delineate the regulatory control of lncRNA degradation, particularly for lncRNA telomeric repeat-containing RNA (TERRA), as the TERRA-telomere R-loops dictate cell cycle progression and genomic stability. We now report that the exosome complex component Exosc9 degrades lncRNA TERRA in human mammary epithelial cells. Heterochromatin protein 1 alpha (HP1α) recruits Exosc9 to the telomeres; specifically, the SUMO-modified form of HP1α supports interaction with Exosc9 and, as previously reported, lncRNA TERRA. The telomeric enrichment of Exosc9 is cell cycle-dependent and consistent with the loss of telomeric TERRA in the S/G2 phase. Elevated Exosc9 is frequently observed and drives the growth of endocrine therapy-resistant (ET-R) HR+ breast cancer (BCa) cells. Specifically, the knockdown of Exosc9 inversely impacts telomeric R-loops and the integrity of the chromosome ends of ET-R cells. Consistently, Exosc9 levels dictate DNA damage and the sensitivity of ET-R BCa cells to PARP inhibitors. In this regard, Exosc9 may serve as a promising biomarker for predicting the response to PARP inhibitors as a targeted monotherapy for ET-R HR+ BCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Nuclear Receptors & Cell Signaling, Department of Biology & Biochemistry, University of Houston, 3517 Cullen Blvd, SERC Bldg, Rm 3010, Houston, TX 77204-5056, USA.
- Engineering Technology College of Technology, University of Houston at Sugarland, 13850 University Blvd, SAB1 Bldg, Rm 348, Sugarland, TX 77479, USA.
ORCID-Profile: Ashfia Fatima Khan, Fatima A Merchant
Förderung
- NCI NIH HHS
- National Cancer Institute of the National Institutes of Health
- Susan G. Komen ASPIRE
Zitieren
APA
Quttina, M., Waiters, K. D., Khan, A. F., Karami, S., Peidl, A. S., Babajide, M. F., Pennington, J., Merchant, F. A., & Bawa-Khalfe, T. (2023). Exosc9 Initiates SUMO-Dependent lncRNA TERRA Degradation to Impact Telomeric Integrity in Endocrine Therapy Insensitive Hormone Receptor-Positive Breast Cancer. Cells. https://doi.org/10.3390/cells12202495
Vancouver
Quttina M, Waiters KD, Khan AF, Karami S, Peidl AS, Babajide MF, et al. Exosc9 Initiates SUMO-Dependent lncRNA TERRA Degradation to Impact Telomeric Integrity in Endocrine Therapy Insensitive Hormone Receptor-Positive Breast Cancer. Cells. 2023. doi:10.3390/cells12202495
BibTeX
@article{Quttina2023,
author = {Quttina, Maram and Waiters, Kacie D and Khan, Ashfia Fatima and Karami, Samaneh and Peidl, Anthony S and Babajide, Mariam Funmi and Pennington, Justus and Merchant, Fatima A and Bawa-Khalfe, Tasneem},
title = {Exosc9 Initiates SUMO-Dependent lncRNA TERRA Degradation to Impact Telomeric Integrity in Endocrine Therapy Insensitive Hormone Receptor-Positive Breast Cancer},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12202495}
}
EUVIMED